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Near Patient Cholesterol Testing in Patients with
Peripheral Arterial Disease
S. D. Hobbs1, A. Jones2, A. B. M. Wilmink1 and A. W. Bradbury1
University Departments of 1Vascular Surgery and 2Biochemistry, Birmingham Heartlands and
Solihull NHS Trust (Teaching), Birmingham, U.K.
Aims: to assess the bias, precision and utility of the Bioscanner 2000 for near patient testing of total cholesterol (NPTC) in
patients with peripheral arterial disease (PAD).
Methods: one hundred consecutive patients attending a hospital-based clinic with symptomatic PAD underwent non-
fasting NPTC using finger prick blood sample and a laboratory total cholesterol (TC) using blood drawn from an
antecubital fossa vein.
Results: the Bioscanner 2000 showed good precision with a coefficient of variation of 1.8±3.8%. NPTC was significantly
lower than laboratory TC (mean (S.D.) 4.67 (1.1) vs. 5.12 (1.2) mmol/l), p 0.01, paired Student's t-test. Comparing the
two methods using Deming regression revealed a 15% negative bias for the Bioscanner 2000 compared to laboratory testing,
which was demonstrated to be a systematic bias using a Bland-Altman plot. Almost half (46%) of the readings differed by
40.5 mmol/l, 16% by41.0 mmol/l and 3% by 42 mmol/l. This means that if the cut-off for statin treatment were taken as
a TC of 5.0 or 3.5 mmol/l then, based on NPTC, alone 18 and 6% of patients, respectively, would not have received a statin.
Conclusions: in the present study, NPTC significantly under-estimated TC when compared to laboratory testing.
However, in the majority of cases, this would not have affected the decision to prescribe a statin and NPTC testing allows
the immediate institution or titration of statin treatment.
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Introduction
The Heart Protection Study (HPS) has shown beyond
reasonable doubt that Simvastatin 40 mg daily, when
compared to placebo, significantly reduces cardiovas-
cular morbidity and mortality in patients with symp-
tomatic atherosclerosis, including peripheral arterial
disease (PAD).1 This effect was independent of age,
gender, diabetic status and baseline total cholesterol
(TC) down to 3.5 mmol/l. The data imply that virtually
all patients with PAD should be on a statin. However,
at the present time, only a minority of PAD patients
are treated, and in a significant proportion of patients
that are treated, the dose of statin prescribed is insuffi-
cient to achieve an adequate (425%) reduction in TC.2,3
The reasons for this include a lack of knowledge
regarding the benefits of statins, concerns about side
effects and costs, and the inconvenience of measuring
TC, especially in primary care. Near patient testing for
total cholesterol (NPTC) is able to overcome the delays
associated with laboratory assays and therefore,
allows for the immediate institution of appropriate
treatment. The aim of this study was to assess the
bias, precision and utility of NPTC in patients with
PAD as part of a hospital-based one-stop clinic.
Patients and Methods
The Bioscanner 2000 (Polymer Technology Systems
Inc., Indianapolis, U.S.A.) is a handheld, battery-
operated instrument that uses reflectance photometry
to measure the concentration of TC on disposable
analyte strips (Fig. 1). The manufacturers claim that
the instrument is accurate (1% bias) when compared
to laboratory methods and that the coefficient of
variation (CV) is less than 3%. Cholesterol control
solutions are used as a quality control to verify the
test system performance.
A single operator prospectively studied 100 con-
secutive non-fasting patients attending a hospital-
based one-stop claudication clinic with symptomatic
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PAD over a 4-month period. The pulp of a distal
phalanx was prepared with a Steret (Seton Healthcare
Group plc, Oldham, U.K.) alcoholic wipe and allowed
to dry. A sample of blood was then obtained using a
sterile lancet without excessive milking of the finger
and the cholesterol concentration was determined
using the Bioscanner 2000 as per the manufacturer's
guidelines. Immediately afterwards, patients had
blood drawn from an antecubital vein and TC was
measured by automated cholesterol ester-oxidase
enzymatic procedure on a Roche P800 analyser (Roche
Diagnostics, Lewes, U.K.).
We tested the within-batch precision of the Bioscan-
ner 2000 by performing two sets of 10 consecutive
assays using two different fixed concentration choles-
terol control solutions (Polymer Technology Systems
Inc., Indianapolis, U.S.A.). The precision of the Bio-
scanner 2000 was determined by calculating the CV,
which is derived from the standard deviation and the
mean of the 10 consecutive assays.
The cholesterol results obtained from the Bioscan-
ner 2000 and the laboratory were compared directly
using a paired Student's t-test. Agreement between
the lipid values obtained was determined by
Deming regression using the `` Analyse-it'' package for
Microsoft Excel. The Deming regression is useful for
comparing variables that are both measured with
error and gives only one regression line independent
of whether x or y is used as the independent variable.
In addition, the results were depicted graphically on a
Bland-Altman plot, in which the difference between
each pair of measurements is plotted against their
mean. The Bland-Altman approach is useful for deter-
mining whether the two methods of measurement
agree sufficiently closely. If the measurements are
comparable, the differences should be small, centred
around zero, and show no systematic variation with
the mean of the measurement pairs.4
Results
The demography, clinical details and drug history of
the cohort of patients are shown in Table 1. NPTC was
significantly lower than laboratory TC (mean (s.d.)
4.67 (1.1) vs. 5.12 (1.2) mmol/l), p 0.01, paired
Student's t-test) (Table 2). Almost half (46%) of the read-
ings differed by 40.5 mmol/l, 16% by 41.0 mmol/l
and 3% by 42 mmol/l. Biases for NPTC as calculated
by Deming regression analysis were high (15%) com-
pared to laboratory values (Fig. 2) and greater than the
3% standard set by the National Cholesterol Educa-
tion Program (NCEP) guidelines.5 The Bland-Altman
plot suggests that the bias between NPTC and the
laboratory TC is systematic with a constant variance
at all levels of measurement (Fig. 3). The laboratory
assay has a positive bias of 2.4% compared to the mean
Fig. 1. Bioscanner 2000 (Polymer Technology Systems Inc.,
Indianapolis, U.S.A.).
Table 1. Demographic details of patients recruited.
Variable
Mean age (s.d.) 68.7 (10.3)
Sex (M:F ratio) 1.6:1
Diagnosis
Intermittent claudication 82
Critical limb ischaemia 4
Cerebrovascular disease 4
Abdominal aortic aneurysm 6
Mesenteric ischaemia 1
Smoking status
Current smoker 40
Ex-smoker 44
Non-smoker 16
Antiplatelet agent
Single 77
Combination 4
None 19
Statin 44
Table 2. Laboratory and near patient total cholesterol values,
precision, bias, variability and cost.
Variable Laboratory
assay
Near patient
assay
p
Total cholesterol (mmol/l)
Range 2.7±8.0 2.8±7.5
Mean SD 5.12 1.18 4.67 1.11 50.001
Coefficient of variation (%) 2.3±2.4 1.8±3.8
Bias (%)  2.4y ÿ 15.3
Unit cost per assay £3.50 £1.66
Paired Student's t-test.
yData from U.K.-NEQAS for Clinical Chemistry, Birmingham.
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of all U.K. laboratories (U.K.-NEQAS for Clinical
Chemistry, Birmingham, U.K.).
The within-batch precision of the Bioscanner 2000
as quantified by the CV was 1.8% at a mean TC of
4.2 mmol/l and 3.8% at a mean TC of 6.2 mmol/l
(Table 2). The Roche P800 analyser used in our labora-
tory has a between-batch precision of 2.4% at a mean
cholesterol of 2.65 mmol/l, and a CV of 2.3% at a mean
cholesterol of 5.95 mmol/l. Between-batch CVs tend to
be higher than within-batch CVs.
The unit reagent cost per assay for the Bioscanner is
£1.66 and the total National Health Service (NHS) cost
for the laboratory assay is £3.50 (including reagents,
labour and indirect costs).
Discussion
This study compares the Bioscanner 2000, a NPTC
assay with a standard laboratory-based assay. NPTC
measurements were statistically different from the
corresponding laboratory measurements with the
Bioscanner 2000 significantly underestimating the TC
concentration. The CV for the Bioscanner 2000 varies
between 1.8 and 3.8%. This compares favourably with
the laboratory CV of 2.4% and suggests that this
method is reproducible when repeated measurements
are made.
We have demonstrated that the Bioscanner 2000
has a significant negative bias compared to laboratory
methods with NPTC values being approximately 15%
lower than those measured in the laboratory. From
analysis of the Bland-Altman plot this bias appears
to be systematic, showing a constant variation at all
levels of cholesterol measurement.
Is this bias of clinical significance? The National
Service Framework for coronary heart disease recom-
mend a cut-off for instigation of cholesterol lowering
therapy of a TC of 5 mmol/l or an LDL cholesterol of
3 mmol/l.6 This figure is based on subgroup analysis
from The Cholesterol and Recurrent Events (CARE)
study.7 The recently published and widely publicised
Medical Research Council and British Heart Founda-
tion funded HPS included patients with a TC cut-off
value of 3.5 mmol/l and showed that treatment with
40 mg of Simvastatin reduced cardiovascular events
by one quarter in patients with symptomatic occlusive
vascular disease.1 The mean reduction in TC in the
statin group of the HPS was 1.2 mmol/l (20% of
the baseline level), however, if non-compliance and
Fig. 2. Deming regression of laboratory total cholesterol versus near patient for total cholesterol (NPTC).
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crossover treatment is considered then the mean
reduction in TC was closer to 25% of the baseline
level.1 If the cut-off for statin treatment were taken as
a TC of 5.0 or 3.5 mmol/l then, based on NPTC alone,
18 and 6% of patients respectively, in the study group
might not have received appropriate statin treatment.
In this study population, only five patients had a TC
measurement of 53.5 mmol/l on laboratory assays,
with three of these already receiving statin therapy at
the time of measurement. Thus 96% (54/56) of pati-
ents not receiving a statin at the time of testing would
benefit from statin treatment as part of their best
medical therapy.
It is likely that the lipid-lowering effects of statins
only partially explain their protective benefit and it
is possible that in the future, the cut-off value of
3.5 mmol/l will be lowered further, or even abolished.
The result of this is that all patients with symptomatic
vascular disease may derive benefit from statin treat-
ment regardless of their starting cholesterol level.
Statins are a complex group of drugs that exert pleo-
tropic effects. In addition to their lipid lowering effects,
they are also known to alter endothelial function and
to have anti-inflammatory and immune modulatory
properties8,9 and reduce the expression of matrix
metalloproteinases.10 Hence statins may have a role
in stabilising atherosclerotic plaques and reducing the
incidence of plaque rupture.
This raises the question of whether there is any need
to measure TC at all. The vast majority of patients with
PAD have a TC 43.5 mmol/l, so based on current
evidence, virtually all patients with PAD should be
treated with a statin. Consequently, the baseline chol-
esterol level is not required to be known in most cases
in order to commence statin therapy in the outpatient
setting. This does not however mean that we can aban-
don testing altogether. Measurement of baseline TC is
essential to act as a reference to ensure that an adequate
(425%) reduction in TC occurs during statin treat-
ment. Furthermore, it is important to pick up the
small subgroup of patients with extremely high TC or
triglyceride levels, who require referral to a lipid clinic.
Based on current evidence, we recommend that all
patients newly diagnosed with PAD should undergo
full laboratory lipid profile analysis. A random sam-
ple is sufficient for TC and HDL-cholesterol since this
shows little daily variation,11 however, if the triglycer-
ide or calculated LDL-cholesterol levels are elevated
then these need to be confirmed on a fasting blood
sample. All patients with a TC 43.5 mmol/l should
be commenced on a statin and treatment should be
monitored in the outpatient clinic to ensure compliance
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Fig. 3. Bland-Altman plot of laboratory cholesterol vs. near patient cholesterol measurement.
270 S. D. Hobbs et al.
Eur J Vasc Endovasc Surg Vol 26, September 2003
and adequate treatment. If the TC has not been
reduced by 25% from baseline then the statin dose
should be increased. We advocate the routine use of
NPTC in the vascular outpatient setting, primary care
or within nurse led clinics to monitor response to
statin therapy. Providing the limitations of the assay
are appreciated and a correction factor is used then
immediate institution or adjustment of statin treat-
ment can be made.
In conclusion, the Bioscanner 2000 showed good
precision but systematically underestimated TC by
approximately 15% when compared to laboratory test-
ing. In the majority of cases, use of NPTC alone would
not have affected the decision to prescribe a statin.
NPTC testing allows immediate institution and titra-
tion of statin treatment.
Acknowledgement
We would like to thank Mr Tim Marshall, statistician from the Public
Health and Epidemiology Department, The University of Birmingham
for his help with the statistical analysis.
References
1 Heart Protection Study Collaborative Group, MRC/BHF
Heart Protection Study Cholesterol Lowering with simvastatin in
20 536 high-risk individuals: a randomised placebo-controlled
trial. Lancet 2002; 360(9326): 7±22.
2 Burns PJ, Lima E, Bradbury AW. What constitutes best medical
therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg
2002; 24: 6±12.
3 Burns PJ, Lima E, Bradbury AW. Second best medical therapy.
Eur J Vasc Endovasc Surg 2002; 24: 400±404.
4 Bland JM, Altman DG. Statistical methods for assessing agree-
ment between two methods of clinical measurement. Lancet 1986;
1: 307±310.
5 Bachorik PS, Ross JW. National Cholesterol Education Program
recommendations for measurement of low-density lipoprotein
cholesterolf executive summary. Clin Chem 1995; 41: 1414±1420.
6 National Service Framework for Coronary Heart Disease.
Department of Health, London, 2002.
7 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,
Cole TG et al. The effect of pravastatin on coronary events after
myocardial infarction in patients with average cholesterol levels.
New Engl J Med 1996; 335: 1001±1009.
8 Vaughan CJ, Murphey MB, Buckley BM. Statins do more than
just lower cholesterol. Lancet 1996; 348: 1079±1082.
9 Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S.
Modulation of inflammatory mediators and PPARgamma
and NFkappaB expression by pravastatin in response to lipo-
proteins in human monocytes in vitro. Pharmacol Res 2002; 45(2):
147±154.
10 Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S,
Ishizuka N et al. A 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor, cerivastatin, suppresses production of matrix
metalloproteinase-9 in human abdominal aortic aneurysm wall.
J Vasc Surg 2002; 36(1): 158±163.
11 Emberson JR, Whincup PH, Walker M, Thomas M,
Alberti KG. Biochemical measures in a population-based
study: effect of fasting duration and time of day. Ann Clin
Biochem 2002; 39: 493±501.
Accepted 12 May 2003
Near Patient Cholesterol Testing in Patients with Peripheral Arterial Disease 271
Eur J Vasc Endovasc Surg Vol 26, September 2003
